Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents

Targeted Oncology

Volumn 5, Issue 1, 2010, Pages 65-72

  Le Tourneau, Christophe ^a   Diéras, Véronique ^a   Tresca, Patricia ^a   Cacheux, Wulfran ^a   Paoletti, Xavier ^a  

^a INSTITUT CURIE   (France)

Author keywords

Dose escalation methods; End points; Methodology; Molecularly targeted agents; Phase I trials

Indexed keywords

6 O BENZYLGUANINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CYTOTOXIC AGENT; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; IMATINIB; OLAPARIB; TEMSIROLIMUS;

ADENOID CYSTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL DEVELOPMENT PLAN; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; FATIGUE; GASTROINTESTINAL TOXICITY; GLIOMA; HUMAN; KIDNEY CARCINOMA; METASTASIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); NEOPLASMS; TRENDS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DRUG DOSAGE CALCULATIONS; HUMANS; NEOPLASMS;

EID: 77952889757     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0137-6     Document Type: Review

References (66)

1. JA DiMasi HG Grabowski 2007 Economics of new oncology drug development J Clin Oncol 25 209 216 10.1200/JCO.2006.09.0803 17210942 (Pubitemid 350003036)
2. DD Von Hoff 1998 There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal Foundation Award Lecture Clin Cancer Res 4 1079 1086
3. M Ranson LA Hammond D Ferry, et al. 2002 ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 20 2240 2250 10.1200/JCO.2002.10.112 1:CAS:528:DC%2BD38XktVKrsrc%3D 11980995 (Pubitemid 34441651)
4. N Thatcher A Chang P Parikh, et al. 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537 10.1016/S0140-6736(05)67625-8 1:CAS:528:DC%2BD2MXhtFKhsbfP 16257339 (Pubitemid 41540110)
5. FA Shepherd J Rodrigues Pereira, et al. 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D 16014882 (Pubitemid 41058344)
6. TJ Lynch DW Bell R Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 139 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D 15118073 (Pubitemid 38637993)
7. JG Paez PA Jänne JC Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D 15118125 (Pubitemid 38720929)
8. W Pao V Miller M Zakowski, et al. 2004 EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 13306 13311 10.1073/pnas.0405220101 1:CAS:528:DC%2BD2cXnvFems70%3D 15329413 (Pubitemid 39209661)
9. IC Henderson DA Berry GD Demetri, et al. 2003 Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 983 10.1200/JCO.2003.02.063 1:CAS:528: DC%2BD2cXpsVGqs7c%3D 12637460 (Pubitemid 46594124)
10. B Fisher S Anderson DL Wickerham, et al. 1997 Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22 J Clin Oncol 15 1858 1869 1:CAS:528:DyaK2sXjsVClsbc%3D 9164196
11. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf
12. EL Strevel DJ Ing LL Siu 2007 Molecularly targeted oncology therapeutics and prolongation of the QT interval J Clin Oncol 25 3362 3371 10.1200/JCO.2006.09.6925 1:CAS:528:DC%2BD2sXhtVWqs7nI 17664484 (Pubitemid 47325624)
13. EL Strevel LL Siu 2009 Cardiovascular toxicity of molecularly targeted agents Eur J Cancer 45 Suppl 1 318 331 10.1016/S0959-8049(09)70046-2 19775628
14. A Asnacios S Naveau G Perlemuter 2009 Gastrointestinal toxicities of novel agents in cancer therapy Eur J Cancer 45 Suppl 1 332 342 10.1016/S0959-8049(09)70047-4 19775629
15. S Segaert G Chiritescu L Lemmens, et al. 2009 Skin toxicities of targeted therapies Eur J Cancer 45 Suppl 1 295 308 10.1016/S0959-8049(09)70044-9 19775626
16. J Carles R Morales JM Perez, et al. 2009 Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities Eur J Cancer 45 Suppl 1 309 317 10.1016/S0959-8049(09)70045-0 19775627
17. TG Roberts Jr BH Goulart L Squitieri, et al. 2004 Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials JAMA 292 2130 2140 10.1001/jama.292.17.2130 1:CAS:528:DC%2BD2cXpsVKksbY%3D 15523074 (Pubitemid 39435104)
18. E Horstmann MS McCabe L Grochow, et al. 2005 Risks and benefits of phase I oncology trials, 1991 through 2002 N Engl J Med 352 895 904 10.1056/NEJMsa042220 1:CAS:528:DC%2BD2MXhvFOhtrc%3D 15745980 (Pubitemid 40300298)
19. S Postel-Vinay HT Arkenau D Olmos, et al. 2009 Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer 100 1373 1378 10.1038/sj.bjc.6605030 1:CAS:528:DC%2BD1MXltFGit70%3D 19401696
20. C Le Tourneau L Vidal LL Siu 2008 Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents Drug Resist Updat 11 99 109 10.1016/j.drup.2008.04.001 18515176
21. MJ Ratain RH Glassman 2007 Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res 13 6545 6548 10.1158/1078-0432.CCR-07-2133 1:CAS:528:DC%2BD2sXhtlSmu7jP 18006752 (Pubitemid 350206786)
22. BJ Druker M Talpaz DJ Resta, et al. 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037 10.1056/NEJM200104053441401 1:CAS:528: DC%2BD3MXivFGnu70%3D 11287972 (Pubitemid 32267972)
23. MB Atkins M Hidalgo WM Stadler, et al. 2004 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 909 918 10.1200/JCO.2004.08.185 1:CAS:528:DC%2BD2cXpsVKisr0%3D 14990647 (Pubitemid 41103603)
24. F Kabbinavar HI Hurwitz L Fehrenbacher, et al. 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65 10.1200/JCO.2003.10.066 1:CAS:528:DC%2BD2cXpsVWru7Y%3D 12506171
25. S Sleijfer E Wiemer 2008 Dose selection in phase I studies: why we should always go for the top J Clin Oncol 26 1576 1578 10.1200/JCO.2007.15.5192 18332465
26. BH Goulart JW Clark HH Pien, et al. 2007 Trends in the use and role of biomarkers in phase I oncology trials Clin Cancer Res 13 6719 6726 10.1158/1078-0432.CCR-06-2860 1:CAS:528:DC%2BD2sXhtlSmu7bL 18006773 (Pubitemid 350206809)
27. G Sauter J Lee JM Bartlett, et al. 2009 Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol 27 1323 1333 10.1200/JCO.2007.14.8197 1:CAS:528:DC%2BD1MXktFKhsbs%3D 19204209
28. CJ Allegra JM Jessup MR Somerfield, et al. 2009 American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2091 2096 10.1200/JCO.2009.21.9170 19188670
29. SJ Mandrekar DJ Sargent 2009 Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges J Clin Oncol 27 4027 4034 10.1200/JCO.2009.22.3701 19597023
30. WR Parulekar EA Eisenhauer 2004 Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice J Natl Cancer Inst 96 990 997 1:CAS:528:DC%2BD2cXlsFyisrs%3D 15240782
31. C Le Tourneau JJ Lee LL Siu 2009 Dose escalation methods in phase I cancer clinical trials J Natl Cancer Inst 101 708 720 10.1093/jnci/djp079 19436029
32. MS Gordon K Margolin M Talpaz, et al. 2001 Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer J Clin Oncol 19 843 850 1:CAS:528:DC%2BD3MXhtlGrt7k%3D 11157038
33. CH Takimoto 2009 Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development Eur J Cancer 45 Suppl 1 436 438 10.1016/S0959- 8049(09)70080-2 19775662
34. AA Adjei 2006 What is the right dose? The elusive optimal biologic dose in phase I clinical trials J Clin Oncol 24 4054 4055 10.1200/JCO.2006.07.4658 1:CAS:528:DC%2BD28XhtVantbzJ 16943522 (Pubitemid 46622278)
35. CM Booth AH Calvert G Giaccone, et al. 2008 Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT) Eur J Cancer 44 19 24 10.1016/j.ejca.2007. 07.034 1:CAS:528:DC%2BD2sXhsVOrurvP 17890079 (Pubitemid 350256933)
36. MA Graham P Workman 1992 The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies Ann Oncol 3 339 347 1:STN:280: DyaK38zhtl2jtw%3D%3D 1616887
37. M Agrawal C Grady DL Fairclough, et al. 2006 Patients' decision-making process regarding participation in phase I oncology research J Clin Oncol 24 4479 4484 10.1200/JCO.2006.06.0269 16983117 (Pubitemid 46630987)
38. ZA Nurgat W Craig NC Campbell, et al. 2005 Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy Br J Cancer 92 1001 1005 10.1038/sj.bjc.6602423 1:CAS:528:DC%2BD2MXisVyisbo%3D 15770219 (Pubitemid 40546660)
39. C Daugherty MJ Ratain E Grochowski, et al. 1995 Perceptions of cancer patients and their physicians involved in phase I trials J Clin Oncol 13 1062 1072 1:STN:280:DyaK2M3ls12htw%3D%3D 7738612
40. P Hamberg J Verweij 2009 Phase I drug combination trial design: walking the Ttightrope J Clin Oncol 27 4441 4443 10.1200/JCO.2009.23.6703 19704054
41. RI Haddad RB Tishler C Norris, et al. 2009 Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck J Clin Oncol 27 4448 4453 10.1200/JCO.2009.22.1333 1:CAS:528:DC%2BD1MXhtlCnsrfP 19704061
42. HT Arkenau D Olmos JE Ang, et al. 2008 Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience Br J Cancer 98 1029 1033 10.1038/sj.bjc.6604218 1:CAS:528:DC%2BD1cXjtlGkt7k%3D 18349817 (Pubitemid 351399798)
43. A Italiano C Massard R Bahleda, et al. 2008 Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy Ann Oncol 19 787 792 10.1093/annonc/mdm548 1:STN:280:DC%2BD1c3gsVOjtQ%3D%3D 18042834 (Pubitemid 351467383)
44. PC Fong DS Boss TA Yap, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 123 134 10.1056/NEJMoa0900212 1:CAS:528:DC%2BD1MXosVKrtrw%3D 19553641
45. DD Von Hoff PM LoRusso CM Rudin, et al. 2009 Inhibition of the hedgehog pathway in advanced basal-cell carcinoma N Engl J Med 361 1164 1172 10.1056/NEJMoa0905360
46. M Dong Z Ning MJ Newman, et al. 2009 Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas J Clin Oncol 27 15s 10.1200/JCO.2008.20.1111 abstract 3529
47. SF Dent EA Eisenhauer 1996 Phase I trial design: are new methodologies being put into practice? Ann Oncol 7 561 566 1:STN:280:DyaK2s%2FjtlOisg%3D%3D 8879368
48. EA Eisenhauer PJ O'Dwyer M Christian, et al. 2000 Phase I clinical trial design in cancer drug development J Clin Oncol 18 684 692 1:CAS:528: DC%2BD3cXht1Kmtbs%3D 10653884
49. A Rogatko D Schoeneck W Jonas, et al. 2007 Translation of innovative designs into phase I trials J Clin Oncol 25 4982 4986 10.1200/JCO.2007.12.1012 17971597 (Pubitemid 350220431)
50. R Simon B Freidlin L Rubinstein, et al. 1997 Accelerated titration designs for phase I clinical trials in oncology J Natl Cancer Inst 89 1138 1147 10.1093/jnci/89.15.1138 1:CAS:528:DyaK2sXls1WnurY%3D 9262252
51. JM Collins CK Grieshaber BA Chabner 1990 Pharmacologically guided phase I clinical trials based upon preclinical drug development J Natl Cancer Inst 82 1321 1326 10.1093/jnci/82.16.1321 1:STN:280:DyaK3czjvFGjtw%3D%3D 2143234
52. J O'Quigley M Pepe L Fisher 1990 Continual reassessment method: a practical design for phase 1 clinical trials in cancer Biometrics 46 33 48 10.2307/2531628 2350571 (Pubitemid 20245604)
53. J Babb A Rogatko S Zacks 1998 Cancer phase I clinical trials: efficient dose escalation with overdose control Stat Med 17 1103 1120 10.1002/(SICI)1097- 0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9 1:STN:280: DyaK1c3ot1Cqtg%3D%3D 9618772 (Pubitemid 28221028)
54. HS Friedman DM Kokkinakis J Pluda, et al. 1998 Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma J Clin Oncol 16 3570 3575 1:CAS:528:DyaK1cXnsVOgtrc%3D 9817277
55. S Hunsberger LV Rubinstein J Dancey, et al. 2005 Dose escalation trial designs based on a molecularly targeted endpoint Stat Med 24 2171 2181 10.1002/sim.2102 15909289 (Pubitemid 40960214)
56. MY Polley YK Cheung 2008 Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests Biometrics 64 232 241 10.1111/j.1541-0420.2007.00827.x 17573866 (Pubitemid 351316860)
57. W Zhang DJ Sargent S Mandrekar 2006 An adaptive dose-finding design incorporating both toxicity and efficacy Stat Med 25 2365 2383 10.1002/sim.2325 16220478 (Pubitemid 44057044)
58. PF Thall JD Cook 2004 Dose-finding based on efficacy-toxicity trade-offs Biometrics 60 684 693 10.1111/j.0006-341X.2004.00218.x 15339291 (Pubitemid 39181113)
59. SJ Mandrekar Y Cui DJ Sargent 2007 An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations Stat Med 26 2317 2330 10.1002/sim.2707 17016867 (Pubitemid 46730251)
60. G Yin Y Li Y Ji 2006 Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios Biometrics 62 777 787 10.1111/j.1541-0420.2006.00534.x 16984320 (Pubitemid 44410635)
61. PF Thall RE Millikan P Mueller, et al. 2003 Dose-finding with two agents in Phase I oncology trials Biometrics 59 487 496 10.1111/1541-0420.00058 14601749 (Pubitemid 37093387)
62. X Huang S Biswas Y Oki, et al. 2007 A parallel phase I/II clinical trial design for combination therapies Biometrics 63 429 436 10.1111/j.1541-0420.2006. 00685.x 1:CAS:528:DC%2BD2sXhtVCqs7%2FE 17688495 (Pubitemid 47222559)
63. Y Yuan G Yin 2008 Sequential continual reassessment method for two-dimensional dose finding Stat Med 27 5664 5678 10.1002/sim.3372 18618901
64. G Yin YA Yuan 2009 Latent contingency table approach to dose finding for combinations of two agents Biometrics 65 866 875 10.1111/j.1541-0420.2008.01119. x 18759848
65. N Houede PF Thall H Nguyen, et al. 2009 Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials Biometrics 10.1111/j.1541-0420.2009.01302.x 19673865
66. SA Cannistra 2008 Challenges and pitfalls of combining targeted agents in phase I studies J Clin Oncol 26 3665 3667 10.1200/JCO.2008.17.2676 1:CAS:528:DC%2BD1cXhtVGjs7zL 18669449